Oncolytics Biotech (ONCY) Long-Term Investments (2009 - 2010)
Oncolytics Biotech (ONCY) posted quarterly Long-Term Investments of $684.0 billion for Q3 2010, up 99999900.0% quarter-over-quarter from $684000.0 in Q2 2010.
Oncolytics Biotech (ONCY) Long-Term Investments (2009 - 2010) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Long-Term Investments for 2 consecutive years, with $684.0 billion the latest figure, recorded in Q3 2010.
- In Q3 2010, Long-Term Investments changed N/A year-over-year to $684.0 billion; the TTM figure through Sep 2010 stood at $684.0 billion (changed N/A YoY), while the FY2009 annual figure was $684.0 billion, changed N/A from the prior year.
- Long-Term Investments climbed to $684.0 billion in Q3 2010 per ONCY's latest filing, from $684000.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $684.0 billion in Q4 2009 and bottomed at $684000.0 in Q1 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | 684.00 Bn |
| Jun 30, 2010 | 684,000.00 |
| Mar 31, 2010 | 684,000.00 |
| Dec 31, 2009 | 684.00 Bn |